Cargando…

Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan

Despite recent advances in the range of therapies available for the treatment of multiple myeloma (MM), there are limited data surrounding survival outcomes and baseline characteristics influencing survival in general clinical practice in Japan. The aim of this study was to use electronic medical re...

Descripción completa

Detalles Bibliográficos
Autores principales: Uno, Shuji, Midorikawa, Shuichi, Inoue, Kei, Ichikawa, Daisuke, Ito, Tomoki, Kuroda, Junya, Suzuki, Kenshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231788/
https://www.ncbi.nlm.nih.gov/pubmed/37256880
http://dx.doi.org/10.1371/journal.pone.0285947
_version_ 1785051811702374400
author Uno, Shuji
Midorikawa, Shuichi
Inoue, Kei
Ichikawa, Daisuke
Ito, Tomoki
Kuroda, Junya
Suzuki, Kenshi
author_facet Uno, Shuji
Midorikawa, Shuichi
Inoue, Kei
Ichikawa, Daisuke
Ito, Tomoki
Kuroda, Junya
Suzuki, Kenshi
author_sort Uno, Shuji
collection PubMed
description Despite recent advances in the range of therapies available for the treatment of multiple myeloma (MM), there are limited data surrounding survival outcomes and baseline characteristics influencing survival in general clinical practice in Japan. The aim of this study was to use electronic medical records (EMRs) to examine overall survival (OS) and prognostic factors in Japanese patients with MM. We extracted EMRs in the Real World Data (RWD) database of patients with a confirmed diagnosis of MM and treatment history with bortezomib, thalidomide, and/or lenalidomide. OS and prognostic factors for OS were analyzed using a univariate analysis and decision tree model. Of the 6509 patients in the database with a diagnosis of MM, 1565 were eligible. Patients had a median (range) age of 72 (23–92) years, a median OS of 53.5 months, and a 5-year OS rate of 45.6%. In alignment with previous studies, International Staging System stage and age were prognostic of OS. In addition, platelet and erythrocyte counts, chloride, total protein, C-reactive protein, and lactate dehydrogenase levels were identified as important prognostic factors for OS and were used to pilot a simple prognostic tool. In conclusion, we found that the survival outcomes extracted from EMRs in the RWD of Japanese patients with MM aligned with a previous retrospective study from Japan. Baseline laboratory parameters prognostic for OS were explored with additional factors to International Staging System and age identified. These might be used to optimize treatment selection, although further investigation using additional data sources is required.
format Online
Article
Text
id pubmed-10231788
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-102317882023-06-01 Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan Uno, Shuji Midorikawa, Shuichi Inoue, Kei Ichikawa, Daisuke Ito, Tomoki Kuroda, Junya Suzuki, Kenshi PLoS One Research Article Despite recent advances in the range of therapies available for the treatment of multiple myeloma (MM), there are limited data surrounding survival outcomes and baseline characteristics influencing survival in general clinical practice in Japan. The aim of this study was to use electronic medical records (EMRs) to examine overall survival (OS) and prognostic factors in Japanese patients with MM. We extracted EMRs in the Real World Data (RWD) database of patients with a confirmed diagnosis of MM and treatment history with bortezomib, thalidomide, and/or lenalidomide. OS and prognostic factors for OS were analyzed using a univariate analysis and decision tree model. Of the 6509 patients in the database with a diagnosis of MM, 1565 were eligible. Patients had a median (range) age of 72 (23–92) years, a median OS of 53.5 months, and a 5-year OS rate of 45.6%. In alignment with previous studies, International Staging System stage and age were prognostic of OS. In addition, platelet and erythrocyte counts, chloride, total protein, C-reactive protein, and lactate dehydrogenase levels were identified as important prognostic factors for OS and were used to pilot a simple prognostic tool. In conclusion, we found that the survival outcomes extracted from EMRs in the RWD of Japanese patients with MM aligned with a previous retrospective study from Japan. Baseline laboratory parameters prognostic for OS were explored with additional factors to International Staging System and age identified. These might be used to optimize treatment selection, although further investigation using additional data sources is required. Public Library of Science 2023-05-31 /pmc/articles/PMC10231788/ /pubmed/37256880 http://dx.doi.org/10.1371/journal.pone.0285947 Text en © 2023 Uno et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Uno, Shuji
Midorikawa, Shuichi
Inoue, Kei
Ichikawa, Daisuke
Ito, Tomoki
Kuroda, Junya
Suzuki, Kenshi
Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan
title Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan
title_full Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan
title_fullStr Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan
title_full_unstemmed Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan
title_short Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan
title_sort survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231788/
https://www.ncbi.nlm.nih.gov/pubmed/37256880
http://dx.doi.org/10.1371/journal.pone.0285947
work_keys_str_mv AT unoshuji survivaloutcomesamongpatientswithmultiplemyelomaintheeraofnovelagentsexploratoryassessmentusinganelectronicmedicalrecorddatabaseinjapan
AT midorikawashuichi survivaloutcomesamongpatientswithmultiplemyelomaintheeraofnovelagentsexploratoryassessmentusinganelectronicmedicalrecorddatabaseinjapan
AT inouekei survivaloutcomesamongpatientswithmultiplemyelomaintheeraofnovelagentsexploratoryassessmentusinganelectronicmedicalrecorddatabaseinjapan
AT ichikawadaisuke survivaloutcomesamongpatientswithmultiplemyelomaintheeraofnovelagentsexploratoryassessmentusinganelectronicmedicalrecorddatabaseinjapan
AT itotomoki survivaloutcomesamongpatientswithmultiplemyelomaintheeraofnovelagentsexploratoryassessmentusinganelectronicmedicalrecorddatabaseinjapan
AT kurodajunya survivaloutcomesamongpatientswithmultiplemyelomaintheeraofnovelagentsexploratoryassessmentusinganelectronicmedicalrecorddatabaseinjapan
AT suzukikenshi survivaloutcomesamongpatientswithmultiplemyelomaintheeraofnovelagentsexploratoryassessmentusinganelectronicmedicalrecorddatabaseinjapan